ALLO — Allogene Therapeutics, Inc.

Summary of Allogene Therapeutics, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, Allogene reported $258.3 million in cash, cash equivalents, and investments, with an extended cash runway into 2028.
• Recent Funding: Received an additional $23.7 million from an arbitration outcome and raised $20.7 million through an ATM equity facility.
• Expenses:
  • Q4 R&D expenses were $28.6 million, totaling $150.2 million for the year.
  • Q4 G&A expenses were $13.8 million, totaling $56.8 million for the year.
• Net Loss: Q4 net loss was $38.8 million ($0.17 per share), with a full-year net loss of $190.9 million ($0.87 per share).

2. Strategic Updates and Business Highlights

• Clinical Focus: The company is prioritizing two key programs: SemiCell (ALPHA-3) for large B-cell lymphoma and ALLO-329 for autoimmune diseases.
• SemiCell Study: Aiming to redefine treatment paradigms by testing early intervention in large B-cell lymphoma, with interim results expected in April 2026.
• ALLO-329 Development: Targeting autoimmune diseases with a focus on low or no lymphodepletion, with proof-of-concept data expected in June 2026.
• Community Integration: Emphasizing the off-the-shelf model of SemiCell to enhance accessibility in community cancer centers.

3. Forward Guidance and Outlook

• 2026 Operating Cash Expense: Expected to be approximately $150 million, with GAAP operating expenses around $210 million, including an estimated $35 million in non-cash stock-based compensation.
• Clinical Milestones: Anticipating significant data releases in 2026, including interim results for ALPHA-3 and proof-of-concept data for ALLO-329.

4. Bad News, Challenges, or Points of Concern

• Competitive Landscape: The emergence of CD3 bispecific therapies moving into the frontline may impact the MRD positivity rates and SemiCell's market positioning.
• Execution Risks: The company acknowledges the need for disciplined execution and prioritization of clinical programs, which may limit the pace of development across its pipeline.
• Financial Losses: The substantial net losses indicate ongoing financial challenges, necessitating careful capital management.

5. Notable Q&A Insights

• Safety Parameters: The upcoming interim analysis will focus on high-level safety data, particularly regarding outpatient delivery and adverse events.
• MRD Analysis: The company aims for a 25% to 30% improvement in MRD clearance compared to the control group, aligning with recent studies that indicate a correlation between MRD clearance and clinical outcomes.
• Community Adoption: There is optimism about the community's ability to adopt SemiCell, with ongoing integration efforts and positive feedback from physicians.
• Spontaneous MRD Conversion: Anticipated rates of spontaneous MRD conversion in the observation arm of the ALPHA-3 study are modeled at around 20%.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A session, providing a balanced view of Allogene Therapeutics' current status and outlook.